PrimeVigilance, an Ergomed company is pleased to promote the upcoming unique and highly focused ISoP two-days seminar, that will explore process automation and AI in the Pharmacovigilance Lifecycle, The topic will be debated by a team of specialists, chaired by Dr Jan Petracek, PrimeVigilance Strategic Advisor and an ISoP Board member.

This seminar will take place at the Biogen Building, 8 Auditorium, Cambridge, MA.

The course will start on 2nd December at 08.00 through to 17.00 and continue on 3rd December at 09.00 through to 17.00

About the seminar:

The hype is over, and the day to day use of automation is now a reality for most. Although implementation speed and success vary significantly from company to company, excitement is growing across the board, and early successes are very encouraging.
This scientific seminar brings together leading regulators, leaders in drug safety and experts from major technology and service providers to exchange views and ideas to get ready for the near- and mid-term future of pharmacovigilance.
The first day will focus on exploration of technological and regulatory advances, and the second day will explore the impact of these changes on organizations and the pharmacovigilance system overall. It will be a joint programme with the Annual Meeting of North America’s Chapter of ISoP (NASoP), allowing leaders in PV to conveniently attend the Annual Meeting as well as the Seminar.

PrimeVigilance would like to extend its gratitude to Biogen for hosting the meeting at its premises for the third time in a row.

The faculty consists of international experts in pharmacovigilance, representing government, academia, and industry.

We encourage you to register!

To register and to see the agenda please visit : ISoP website

Please have in mind the auditorium is limited to 60 participants, to encourage interaction, networking, and exchange of invaluable insights.
For practical information, the program and registration forms are available by contacting: administration@isoponline.org

 


PREVIOUS NEWS:

This site uses cookies to personalise and customise your experience. No cookies collect personal or sensitive information. By clicking “I Accept", you consent to cookies in accordance with our cookie policy.